No abstract

Introduction Fatigue is one of the most frequent symptoms in anti-cancer immune therapy. Physical activity has been proven effective in reducing fatigue, but unmet needs remain regarding the provision and access to adapted programmes, which efficiently addresses the main barriers to PA. Methods The PACTIMe-FEAS study primarily aimed at primarily to evaluate the feasibility and the acceptability of a videoconference-based 6-month programme promoting physical activity, and secondarily to assess its potential post-immediate and short-term effectiveness in reducing fatigue in cancer patients under immune therapy. Numeric self-reported questionnaires (Visual Analogue Scale-fatigue, Multidimensional Fatigue Inventory, International Physical Activity Questionnaire, Échelle de Motivation envers l’Activité Physique en contexte de Santé, Medical Outcomes Study 36-Item Short Form Health Survey, Hospital Anxiety and Depression Scale and Insomnia Severity Index) were completed by participants through an online secure platform at three time points: just before (T1), and after (T2) the programme, and 3 months later (T3). Results Sixteen participants (50% male, 50% female, mean age 54 years, 69% melanoma, 31% overweight), with moderate-to-severe fatigue, entered the internet-delivered intervention; 14 completed it, with an average completion rate of physical activity supervised sessions of 75%. Satisfaction was high, confirming a demand for group format, personalised approach, professional guidance and home-based device, to support the practice of regular physical activity. A decrease in fatigue was observed at the end of the programme. Discussion The recruitment process did prove to be challenging, with a relatively small eligible population, and will need to be reconsidered to envision a larger scale trial. But here and now, this feasibility study provides the first promising foundations to develop further research on the effectiveness of an original remote programme.

No abstract

A149Objectives: To estimate the cost-effectiveness of sunitinib as first-line treatment for metastatic renal-cell carcinoma (mRCC) from the Colombian health system perspective. MethOds: A Markov model was developed to compare the quality-adjusted life-years (QALYs) of three strategies as first-line treatment for (mRCC): sunitinib (50 mg per day for 4 weeks followed by 2 weeks off-treatment), bevacizumab (10 mg/kg every 2 weeks) combined with interferon alfa-2a (9 MIU subcutaneously three times a week), and pazopanib (800 mg once daily). The efficacy, safety and utility data were taken from published studies. Bayesian mixed treatment comparison method was applied for the indirect comparison among treatments related to efficacy and safety. We used 5 years as time horizon. An annual discounted rate of 5% was applied. All currency units are in USD$ (1 USD$ = COP 2,640). Costs of drug treatment, disease progression and best supportive care were estimated using official tariffs and databases from Colombia. We used as threshold three times the GDP per capita (USD$ 17,043). Results were tested using deterministic and probabilistic sensitivity analyses. Results: The total expected costs per patient were: bevacizumab combined with interferon alfa-2a USD$ 65,302; sunitinib USD$ 62,074 and pazopanib USD$ 61,793. The results for each alternative in terms of QALY were: bevacizumab combined with interferon alfa-2a (1.62); sunitinib (2.28) and pazopanib (2.22). Bevacizumab combined with interferon alfa-2a was a dominated alternative. The ICER/QALY of sunitinib compared to pazopanib was USD$ 4,685. cOnclusiOns: These results suggest that sunitinib as first-line treatment for (mRCC) is cost-effective in Colombia, taking into account the stablished threshold.Objectives: To estimate the potential cost effectiveness of maintenance therapy to prevent disease progression following chemotherapy for malignant mesothelioma (MM). MethOds: Decision analytic modeling was performed using a Markov cohort approach to estimate the incremental cost effectiveness of a post-chemotherapy maintenance therapy for MM, measured as cost per quality-adjusted life years gained. The perspective of the payer was taken. Entering the model were 100 males, age 65 years, having non-progressed MM following completion of a standard regimen chemotherapy. Rate of progression and overall survival were derived from a phase III trial with pemetrexed plus cisplatin, and cycles were 1 month in length. Health utilities represented values used in similar studies, applied to patients with non-progressed and progressed MM health states. We assumed that the maintenance therapy would reduce the rate of disease progression by 25%. As U.S. data regarding health care utilization among patients with MM is lacking, published cost estimates for lung cancer were applied. Outcomes and costs were discounted at 3.5% annually. Sensitivity analyses examined the robustness of the model when varying values were used for the costs of care and medication, and for treatment effectiveness. Resu...

No abstract